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Non-proteolytic ubiquitin signaling mediated by Lys63 ubiq-
uitin chains plays a critical role inmultiple pathways that are key
to the development and activation of immune cells. Our previ-
ouswork indicates thatGPS2 (G-protein Pathway Suppressor 2)
is amultifunctional protein regulatingTNF signaling and lipid
metabolism in the adipose tissue through modulation of Lys63
ubiquitination events. However, the full extent of GPS2-medi-
ated regulation of ubiquitination and the underlying molecular
mechanisms are unknown. Here, we report that GPS2 is
required for restricting the activation of TLR and BCR signaling
pathways and the AKT/FOXO1 pathway in immune cells based
on direct inhibition of Ubc13 enzymatic activity. Relevance of
this regulatory strategy is confirmed in vivo by B cell-targeted
deletion of GPS2, resulting in developmental defects atmultiple
stages of B cell differentiation. Together, these findings reveal
that GPS2 genomic and non-genomic functions are critical for
the development and cellular homeostasis of B cells.
Protein ubiquitination represents a key regulatory strategy
for controlling both innate and adaptive immune responses
(1–3). Ubiquitination is a reversible modification that is
achieved via the sequential actions of several classes of
enzymes, including an ubiquitin (Ub)-activating3 enzyme (E1),
an Ub-conjugating enzyme (E2), and an Ub ligase (E3) (4, 5).
Polyubiquitination of target proteins with chains of different
topology can promote either protein degradation or serve, as in
the case of other post-translational modifications, to influence
protein functions and interactions (6, 7). Among others, the
Lys63-linked ubiquitin chains synthesized by the E2-conjugat-
ing enzyme Ubc13 are non-proteolytic (8). In innate immunity,
non-proteolytic ubiquitination events play a central role in
multiple signaling pathways activated by the recognition of
early response cytokines and infectious agents via cell surface or
intracellular receptors (9–13). These include the TNF receptor
(TNFR) superfamily, the Toll-like receptors (TLRs), NOD-like
receptors (NLRs), and RIG-I-like receptors (RLRs). Similarly,
activation of the B cell antigen receptors (BCRs) and T cell
receptors (TCRs) during adaptive immune responses results
in the activation of complexes that rely on Lys63 ubiquitination
for signal transduction (1, 3, 14–20). These ubiquitination
events represent key nodes in the tight regulation of immune
responses as indicated by the fact that multiple negative regu-
lators impinge on these steps. These regulatory factors are often
deubiquitinases (i.e.A20/TNFAIP3, CYLD, and the newly iden-
tified MYSM1) that help control the signal specificity and pre-
vent the aberrant constitutive activation of pro-inflammatory
responses by removing polyubiquitin chains from their sub-
strates (1, 21–24). Importantly, genetic deletion experiments
have confirmed their anti-inflammatory functions in vivo, and
loss of negative regulation is consistently found associated with
hyperactivation of downstream signaling mediators, including
IKK and NF-B (25–27). Also, based on frequent inactivation
by deletions or somatic mutations in B cell lymphomas, A20/
TNFAIP3 is described as a tumor suppressor required for pre-
venting the constitutive activation of NF-B signaling that is
often used in hematological malignancies as a pro-survival
strategy (28–31).
GPS2 (G-protein Pathway Suppressor 2) was originally iden-
tified while screening for suppressors of Ras activation in the
yeast pheromone response pathway (32). Recent studies by our
lab and others indicate that GPS2 plays an important anti-in-
flammatory role in adipose tissue and macrophages and is
required for the expression of genes regulating cholesterol and
triglyceride metabolism in liver and adipose tissue (33–38).
Because of the multiple functional interactions observed
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between GPS2 and transcriptional regulators, including the
NCoR/SMRT corepressor complex, the histone acetyltrans-
ferase p300, and numerous DNA-binding transcription fac-
tors, GPS2 activity has been mainly studied in the context of its
nuclear functions, including both transcriptional repression
and activation (33–35, 37, 39–46). However, our recent work
has also identified a non-transcriptional role for GPS2 in the
cytoplasm, specifically linkingGPS2with themodulation of the
TNF signaling pathway and the activation of JNK (33). Inter-
estingly, our findings reveal that distinct GPS2 functions in dif-
ferent cellular compartments rely on a conserved regulatory
strategy based on the inhibition of ubiquitin-conjugating com-
plexes that are responsible for the formation of non-degrada-
tive Lys63 ubiquitin chains (TRAF2/Ubc13 in the cytosol and
RNF8/Ubc13 in the nucleus) (33, 37). This raises the questions of
whether GPS2 inhibition of Ubc13-dependent ubiquitination
events extends to other signaling pathways and to what extent
GPS2-mediated regulation of ubiquitin signaling is required in
vivo for the development and homeostasis of immune cells.
Here, we have addressed these questions using B cell-tar-
geted deletion of GPS2 in mice. Our results indicate that in B
cells, GPS2 regulates both the AKT/FOXO1 pathway and the
TLR and BCR signaling pathways via direct inhibition of Ubc13
enzymatic activity. In vivo, GPS2 deletion results in a partial
block in the maturation of bone marrow B cells past the pre-B
cell stage and a significant decrease in splenic marginal zone
(MZ) B cells and peritoneal and splenic B-1 cells caused by
synergistic transcriptional and non-transcriptional effects.
Results
Generation of B Cell-specific GPS2 Knock-out (GPS2-BKO)
Mice—GPS2 plays a key anti-inflammatory role in both liver
and adipose tissue (33, 35, 36). Its relatively high expression
levels in human spleen and leukocyte cells suggest that it could
also play an important role in regulating immune cell functions
(47). However, its relevance in this context has not yet been
investigated. To overcome the early embryonic lethality of
global GPS2 deletion (45) and investigateGPS2 relevance in the
regulation of B cells functions and development, we chose a
conditional deletion approach. Mice specifically deleted for
GPS2 in the B cell lineage were generated by crossing GPS2fl/fl
mice, carrying LoxP sites flanking exon 3–6, with hemizygous
CD19-Cre mice (The Jackson Laboratory). Although insertion
of Cre disrupts the CD19 coding sequence, leading to a CD19
deficiency in the homozygous situation, the CD19-Cre/Cre
mice are phenotypically normal and can be used for B lineage-
specific deletion (48). Overall, GPS2fl/fl-Cre/Cre (GPS2-BKO)
mice are viable, healthy, and fertile. To confirm the specificity
and efficacy of our deletion strategy, B cells were isolated from
the spleens of WT and GPS2-BKO littermates by negative
selection. Visual observation of the spleens did not reveal any
gross anatomical differences, as confirmed by a comparable
splenic index (Fig. 1A). Comparable numbers of total spleno-
cytes and isolated B cells were obtained from GPS2-BKO mice
andWT littermates (Fig. 1, B and C). GPS2-specific deletion in
theB cell lineagewas confirmed through genomic PCRanalysis,
quantitative RT-PCR, and Western blotting of the B cell-posi-
tive and B cell-negative splenocyte fractions (Fig. 1, D–F).
Gene Expression Profiling of Splenic B Cells by RNA
Sequencing—Based on the proposed role of GPS2 as both a reg-
ulator of cytosolic signaling pathways and a transcriptional
cofactor for multiple transcription factors (34, 36, 37, 43, 45,
46), we predicted that GPS2 deletion might have a broad effect
on the B cell transcriptome. To investigate the full profile of
GPS2-regulated genes in our experimental model, we per-
formed an open-ended transcriptomic analysis of the splenic
B cells isolated from WT and GPS2-BKO littermates by
RNA-Seq. Bioinformatic analysis of the RNA sequencing
results revealed 716 differentially expressed (DE) genes (with
5% false discovery rate threshold) that were consistently iden-
tified in three biological replicates profiled in distinct sequenc-
ing experiments (either using Illumina or NEB kits for generat-
ing the cDNA library). Among the DE genes, 198 were found to
be up-regulated, and 518 were found to be down-regulated
(FC  1.1) in GPS2-deficient cells, with GPS2 being, as
expected, the most down-regulated gene (FCs between 2.5
and3.2) (Fig. 1G and supplemental Table S1).
Based on our previous work showing an inhibitory role for
GPS2 towardTRAF2-dependent activation of theTNFR1 path-
way (33), we expected the loss of GPS2 to associate with the
up-regulation of genes downstream of TRAF2 and TNF sig-
naling. In agreement with this hypothesis, pathway analysis for
potential upstream regulators of the DE genes predicted
TRAF2/3 (activation score  2.449) and MAP4K4 (activation
score  2.714) to be up-regulated (supplemental Table S2).
However, GO analysis of the biological processes and cellular
and molecular functions associated with the DE genes revealed
a significant enrichment in terms associated with ribosomal
activity, protein translation, and mitochondrial functions
rather than terms related to inflammation or immune-specific
functions (graph in supplemental Table S3). Accordingly, with
this analysis, the mTORC2 complex subunit RICTOR was also
enriched among the potential upstream regulators of the DE
genes (activation score  4.123) (supplemental Table S2), and
top canonical pathways associated with the DE genes (as iden-
tified by IPA analysis) included EIF2 signaling, mitochondrial
dysfunction, and mTOR signaling (Fig. 1H). Together, these
analyses confirmed unpublished observations in other cell
models that support a general role for GPS2 in regulating
energy metabolism in cells (111).4 More specifically relevant to
the B cell model of this signature, IPA analysis of the top dis-
eases and biological functions that are potentially affected by
this altered gene expression profile predicted defects in “hema-
tological system development and function” in GPS2-BKO
mice, including an arrest in B-lymphocytes development and
differentiation characterized by a potential decrease in “quan-
tity of B-1 lymphocytes” and “quantity of marginal-zone B lym-
phocytes” and an increase in “pre-B lymphocytes” (Fig. 1I and
supplemental Table S4).
Defective B Cell Development in the Bone Marrow of GPS2-
deficient Mice—Based on these predictions, we investigated
whetherGPS2 deletion affects B cell development. To assess for
potential defects during thematuration of B cells, we quantified
4 M. D. Cardamone and V. Perissi, unpublished data.
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B cell subsets in WT and GPS2-BKO. For this we developed a
13-color multicolor flow cytometry panel that allowed us to
identify developing B cell subsets in the bonemarrow (pre pro B
cells, pro B cells, pre B cells, immature B cells, and transitional B
cells), the spleen (B-1a and B-1b; transitional T1, T2, and T3;
marginal zone and marginal zone T2 precursors; and follicular
B cells), and the peritoneal cavity (B-1a, B-1b, and conventional
B-2 cells).
The total numbers of cells recovered from the bone marrow
was not affected byGPS2 deletion (Fig. 2A). Overall, the expres-
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sion of B cell markers in the bone marrow corresponded to a
normal B cell phenotype (Fig. 2B), but the frequency of mature
B cells was slightly reduced in GPS2 mutant mice relative to wild
type as indicated by a decrease in IgM cells and a corresponding
increase in B220IgM populations (Hardy’s Fractions B-D)
(Fig. 2C). In particular, we observed a significant increase in the
frequency of B220lowCD19CD93CD43IgM B cells (pre-B
cells, Hardy’s Fraction D). In the IgM subset, it was the
B220highCD19CD93CD23IgD transitional B cell popula-
tion (Hardy’s fraction F) thatwas decreased, whereas the imma-
ture B cells (B220highCD19CD93CD23IgD, fraction E)
were comparable in WT and GPS2-BKO mice (Fig. 2D).
Together these results reveal that the development of GPS2-
BKO cells is impaired at the pre-BCR stage of the B cell matu-
ration process in the bonemarrow. Interestingly, a similar phe-
notype is promoted by the deletion of FOXO1 in pre-B/
immature cells. Although earlier deletion of FOXO1 results in a
block in B cell development at the pro-B cell stage, CD19-Cre-
driven deletion of FOXO1 is associated with a later impairment
at the pre-B cell stage, defective light  chains rearrangement,
and a lower number of recirculating mature cells (49). Among
the genes significantly altered in splenic GPS2-BKO cells, the
pre-BCR adaptor protein BLNK/SLP-65, the MAPK-activated
kinaseMK5, and the recombination activating geneRAG1were
all known to play key roles in FOXO1-mediated regulation of
the rearrangement of immunoglobulin chains (50–56) (supple-
mental Table S1). This prompted us to investigate the possibil-
ity that lack of GPS2 affects the early stages of B cell differenti-
ation through defective transcriptional regulation of key
FOXO1 target genes. To confirm this hypothesis, we first mea-
sured by RT-qPCR analysis the expression of GPS2 putative
target genes in B cell precursors isolated from the bonemarrow
ofWT and GPS2-BKOmice.GPS2 gene deletion driven by the
CD19-Cre proved less efficient in the bone marrow than the
spleen (Fig. 2E), as expected based on the fact that CD19-Cre
efficiency of recombination has been reported as close to 90% in
mature B cells, 40% in immature B and pre-B cells, and less than
5% in pro B cells (57). However, this down-regulation was suf-
ficient to drive a significant decrease in the expression of
FOXO1 target genes RAG1, RAG2, and BLNK (Fig. 2F). Inter-
estingly, the expression of FOXO1 gene itself was also found
significantly down-regulated in GPS2-depleted cells (Fig. 2F).
Thus, we asked whether GPS2 regulated the transcription of
these genes directly or indirectly through FOXO1-mediated
transcriptional events. Results of our ChIP analysis revealed
significant GPS2 binding to the promoters of BLNK, RAG1,
RAG2, and FOXO1 genes in B cells isolated from the bonemar-
row (Fig. 2G), thus suggesting a direct role for GPS2 in the
transcriptional forward loop that regulate FOXO1 and some of
its target genes in developing B cells. Interestingly, FOXO1
binding on each of these promoters was drastically reduced in
GPS2-BKO cells (Fig. 2H). Although FOXO1 binding to chro-
matinisunlikelytorequirepromoterprimingviahistonedemeth-
ylation as previously reported for PPAR (37), it is well known
that FOXO factors are negatively regulated by the PI3K/AKT
pathway via phosphorylation and nuclear exclusion (50).
Because we recently reported that GPS2 deletion in adipocytes
leads to constitutive AKT activation (111), we asked whether
GPS2-mediated regulation of AKT is conserved in B cells.
Indeed, as shown in Fig. 2I, AKT phosphorylation was found to
be increased in GPS2-BKO cells. Also, as expected in presence
of enhanced AKT activation, we observed a striking up-regula-
tion of FOXO1 phosphorylation, which is consistent with the
loss of FOXO1 binding toDNA inGPS2-deficient cells (Fig. 2I).
In conclusion, GPS2 deletion in the mid-late stages of bone
marrow differentiation causes a mild defect in the transition
from pre-B to immature B cells. In particular, our data indicate
that GPS2 is required during this developmental transition for
the expression of a number of genes that play a key role in the
recombination of immunoglobulin chains and receptor editing.
Intriguingly, GPS2 appears to regulate these genes through
combinatorial genomic and non-genomic functions, including
direct transcriptional regulation via promoter binding and indi-
rect regulation of the PI3K/AKT pathway. This may be a regu-
latory strategy conserved among distinct cell types as indicated
by our recent work about the role of GPS2 in the regulation of
insulin signaling in the adipose tissue and by previousChIP-Seq
data showing GPS2 binding to the FOXO1 promoter in both
human 293 cells and mouse 3T3-L1 adipocytes (33, 37, 111)
(Fig. 2J).
Targeting GPS2 Disrupts the B1 and MZ B Cell Com-
partments—To further characterize the development of B
cells in GPS2-BKO mice, we followed the maturation path-
way of B cells in the spleen, where they differentiate into
either follicular (FO) or MZ B cells. FO cells represent the
majority of mature B-2 cells circulating through blood and
secondary lymphoid organs, whereas MZ cells are non-cir-
culating mature B-2 cells residing in the marginal zone of
splenic follicles (58). Macroscopically, there was no differ-
ence in spleen size between the animal groups, and the cell yield
was consistently comparable (Fig. 1B). However, the cellular com-
position of the splenocyte populations was dramatically different
(Fig. 3A). Resolution of the three different subsets of immature
AA41B-2 cells did not reveal any defect in the transition from
FIGURE 1. Generation of B cell-specific GPS2 knock-out (GPS2-BKO) mice. A, Spleen’s morphology and splenic index from WT and GPS2-BKO mice
calculated as spleen weight/total body weight S.D.; data are representative of n 14 female mice, age 10–16 weeks old. B, cell yield obtained from spleen
preparations. C, flow cytometric analysis of B cells purity after Pan B cell isolation from total splenocytes.D–F, validation of GPS2 deletion in GPS2-BKOmice.D,
PCR analysis of genomic DNA from GPS2flox/flox mice expressing or not expressing one copy of the Cre transgene under control of the CD19 promoter. E,
RT-qPCR analysis of Gps2 gene expression. F, WB for GPS2 (C-terminal antibody) on total cell lysates from B cells isolated by negative selection from total
splenocytes and non-B cell splenocytes (column flow through). Bar graphs represent the sample means of three independent experiments S.D. *, p 0.05;
**, p  0.01. G, heat map showing differentially expressed genes (FC  1.1) in B cells from spleens of WT and GPS2-BKO mice. The results from three
independent biological replicates and separate RNA-Seq experiments are shown, including two cDNA libraries generatedwith Illumina TruSeq stranded total
RNA sample prep kit (Illumina 1 and 2) and one with NEBNext ultra directional library preparation kit (NEB). The heat map was produced using heatmap.2()
functions in R and based on Minkoski distance. See supplemental Table S1 for complete list of DEGs and supplemental Table S2 for upstream regulatory
networks. H, top canonical pathways associated with the DE genes by IPA analysis. I, IPA analysis of DEGs showing a selection of the top biological function
potentially affected in GPS2-KOmice based on their activation Z-score. See supplemental Table S4 for the complete list.
B Cell-specific Knockdown ofMurine GPS2
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T1 to T2 to T3 cells in GPS2-BKO mice (Fig. 3B). However, as
predicted based on the RNA-Seq analysis (Fig. 1I), we observed
almost a 3-fold reduction in the frequency of MZ B cells
(B220CD19IgMhiCD21hiCD23low) in the spleen ofGPS2-BKO
mice compared with wild-type littermates (Fig. 3C). On the con-
trary, the frequency of FO B cells (B220CD19CD21lowCD23hi)
shows a reciprocal increase in GPS2-BKO mice, indicating a
switch between the two cell types in GPS2 mutant mice (Fig.
FIGURE2.DefectiveB cell development in thebonemarrow (BM)ofGPS2-deficientmice.A, cell yield obtained frombonemarrowpreparation.White bars,
WT; black bars, GPS2-BKO (n  7). Bar graphs are S.E., and the p value is calculated by two-tailed t test. B, flow cytometry analysis and gating strategy.
Representative plots are shown. Cells were pregated on a light scatter plot based on their size and granularity, doublets excluded on SSC-H versus SSC-W (side
scatter height versuswidth) andFSC-H versus FSC-W (forward scatter height versuswidth) basis, dead cells excludedbasedon live-deaddye staining, andCD3
and CD11b cells excluded before plotting the remaining live single CD3CD11b lymphocytes on the first plot of the gating sequence. C and D, B cell
subpopulation comparisons.White bars, WT; black bars, GPS2-BKO (n 7). Bar graphs are S.E., and the p value is calculated by two-tailed t test. E and F, GPS2
mRNA expression in BM B cells from GPS2-BKO and control littermates measured by RT-qPCR (E) and validation of putative GPS2 target genes (F) in BM from
GPS2-BKO and control littermates by RT-qPCR. Bar graphs represents the sample mean of three independent experiments S.D. G, ChIP analysis to measure
GPS2 occupancy on the promoters of putative target genes in B cells purified from BM of WTmice. H, ChIP for GPS2 and FOXO1 in B cells purified from BM of
either WT or GPS2-BKO mice. For ChIPs, data are representative of three independent experiments. Bar graphs represents the sample mean of technical
replicates S.D. *, p 0.05; **, p 0.01. I, Western blotting for P-AKT (Ser473) and P-FOXO1 in splenic B cells. J, representative track of GPS2 binding to the
proximal promoter of FOXO1 gene by ChIP-Seq in murine 3T3-L1 differentiated adipocytes (37). The same pattern is observed in undifferentiated 3T3-L1 and
human 293T cells (33, 37).
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3C). In addition, the population of precursor marginal zone B
cells (T2MZ; CD19IgMhighCD21highCD23highCD1d) also
appears increased in frequency in mutant mice, suggesting a
developmental block at this stage (Fig. 3C). In agreement with
the differences observed via flow cytometry analysis, H&E
staining of spleen sections reveals that the spleen architecture is
disrupted inGPS2-deficientmice comparedwith control litter-
mates, with enlarged and not well defined follicular structures
(Fig. 3D). Reduced thickness of the marginal zone and dis-
rupted follicles architecture is also confirmedby staining for the
MZ-specific macrophage marker CD169 (Moma-1) (Fig. 3E).
These results together suggest that within the B-2 conventional
B cell compartment, GPS2 is specifically required for the termi-
nal differentiation of MZ B cells, in addition to B cell perturba-
tions in the bone marrow.
Next, we assessed the B-1 cell population. This population
was also predicted by RNA-Seq analysis to be reduced, and
indeed the CD19CD43B220low B-1 pool was approximately
three times smaller in frequency in the spleens of mutant mice
than in their WT littermates (Fig. 4, A and B). Within this
population, the observed decrease appears to be solely due to
the drop in the percentages of B-1a cells (defined as
CD19CD43B220lowCD5CD23), whereas B-1b cell popu-
lations (CD19CD43B220lowCD5CD23) were similar in
frequencies between the two groups (Fig. 4B). Likewise, we
found B-1a cells to be reduced in the bone marrow of GPS2-
BKO mice (Fig. 4C). Because IL-10 production is a functional
hallmark of B1 cells, we further confirmed this phenotyping by
measuring splenocyte IL-10 production in vitro. Most of B-1a
and more than a half of B-1b cells produced IL-10 upon stimu-
lation, confirming their immunophenotype (Fig. 4D), with no
difference in the proportion of IL-10 cells within the B-1a or
B-1b populations (Fig. 4E). To complete our phenotypic analy-
sis, we also analyzed the B cells circulating through the perito-
neal cavity, where the B-1 population is highly enriched. Again
total cell number was unaffected byGPS2 deletion (Fig. 4F), but
we found a lower frequency of B-1a cells in the peritoneum of
GPS2-BKO mice, similar to results from the spleen and the
bone marrow (Fig. 4, G and H), whereas the B-1b portion of
CD19 cells was simultaneously more than 2-fold higher (Fig.
4H). The B-2 (conventional B cells) fraction of the peritoneal
cavity B cells was similar between the two genotypes.
Lastly, to confirm the objectiveness of the manual flow
cytometry data analysis, we subjected our flow cytometry data
set to the automated data analysis by SPADE (59). Automated
clustering was performed on CD19 events in bone marrow,
spleen, and peritoneal cavity based on the markers whose
expression delineates B cell subsets in those tissues. Upon clus-
tering, all B cell subsets were clearly separated and identified as
such based on the levels of lineage marker expression, with
quantitative differences in cell percentages closely following the
ones identified by blinded manual gating (Fig. 4I and data not
shown).
Together, these analyses confirmed thatGPS2 deletion in the
B cell lineage impairs the development of B cells in the bone
marrow at the stage of pre-B cells, with a mild but significant
reduction in the amount of Transitional B cells recirculating to
the bone marrow. In addition, they revealed that GPS2-BKO
mice are defective in splenic MZ B cells and B-1a B cell com-
partments known as innate-like B cells (ILB) in both the spleen
and the peritoneal cavity.
GPS2 Restricts TLR Signaling through Inhibition of Ubc13
Activity—B-1 and MZ cells together are considered ILB,
because of their ability to respond to thymus-independent anti-
gens and produce large amounts of polyreactive antibodies. In
normal mice, ILBs are the major source of natural antibodies at
steady state, and following TLR stimulation, they increase their
production of IgM and IL-10 (60). To confirm whether the
reduced number of ILBs in GPS2-BKO mice corresponded to
an altered titer of natural antibodies, wemeasured plasma levels
of all major isotype classes in unchallenged mice using the
Milliplex isotyping kit (Millipore). To our initial surprise,
GPS2-KO mice showed a significant increase rather than a
decrease, in IgM levels, in addition to a mild but significant
increase in IgG1 and IgG2b (Fig. 5A). IgG2a and IgG3 also
trended to increase (Fig. 5A). At the same time, we found a
corresponding increase of surface IgM expression per cell on
multiple B cell subsets in GPS2-BKO mice (Fig. 5B). Because
B-1 are the major producers of natural IgM, together with MZ
cells, the significant increase in basal levels of IgM indicated
that the secretory ability of the reduced pool of ILB cells was
substantially increased, thus suggesting that IgM-producing
cells might be constitutively activated in GPS2-BKOmice. This
hypothesis was in accord with our previous work identifying
GPS2 as a negative regulator of the TNFR1 signaling pathway
and potentially other pro-inflammatory pathways (33). Thus,
we asked whether constitutive activation of TLR signaling was
observed in splenic B cells fromGPS2-BKOmice by measuring
the activation of intracellular mediators of TLR signaling. As
shown in Fig. 5C, constitutive activation of critical steps of the
signaling cascade downstream of TLR receptor was indeed
observed upon GPS2 depletion, including a significant increase
in both basal and inducible IB degradation and p38, JNK, and
IKK phosphorylation. In accord with the prediction of consti-
tutively active NF B signaling, sustained basal activation of a
number of NFB target genes, including TNF, iNOS, MCP1,
IL6, and LTA, was also observed in GPS2-deficient resting B
cells (Fig. 5D). Notably, the up-regulation observed in absence
of TLR stimulation is quite small in term of fold changes,
despite being significant, possibly explaining the lack of enrich-
ment in GO terms associated with inflammation among the DE
genes defined by RNA-Seq in unstimulated B cells. To further
confirm increased activation of a functional pro-inflammatory
transcriptional program in absence ofGPS2, we then compared
the activation of known TLRs target genes in response to dif-
ferent ligands uponGPS2 deletion/overexpression. To this end,
we used the following ligands: synthetic triacylated lipopeptide
Pam3CSK4 (Pam3) to activateTLR1/2, bacterial LPS to activate
TLR4, imidazoquinoline compound gardiquimod (Gardi) to
activate TLR7, and CpG oligodeoxynucleotides (ODN 2395) to
activate TLR9, and we measured the expression of known TLR
target genes. First, we analyzed splenic B cells isolated from
wild-type and GPS2-BKO littermates. In the presence of TLR4,
TLR7, andTLR9 stimulation, the activation of TLR target genes
ccl3, ccl4, and IL6 is significantly increased in absence of GPS2
(Fig. 5E). TheGPS2 gene itself was down-regulated upon TLR7
B Cell-specific Knockdown ofMurine GPS2
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stimulation, similar to what previously observed upon TNFR
activation (33). Next, we measured the activation of represen-
tative TLR target genes in bone marrow-derived macrophages
from wild-type and GPS2 overexpressing transgenic mice
(aP2-GPS2) (33). As shown in Fig. 5F, GPS2 overexpression
inhibits the activation of target genes TNF andCD14 (61–64)
under most conditions, also in agreement with GPS2 overex-
pression in macrophages inhibiting the activation of pro-in-
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flammatory genes upon TLR4 stimulation by LPS (33). Thus,
our results indicate that GPS2 is required for restricting signal
transduction downstream of multiple TLR receptors.
We previously showed that GPS2-mediated regulation of
TNFR1 is achieved through inhibition of TRAF2/Ubc13 activ-
ity. Because of the similarities between the TNFR1 and TLR
signaling pathways in terms of usage of non-proteolytic Lys63
ubiquitin signaling for signal transduction, we hypothesized
that GPS2 inhibitory role toward TLR signaling was medi-
ated by a similar mechanism. In support of this hypothesis,
we observed that GPS2 overexpression caused a significant
decrease in the amount of LPS-induced autoubiquitination,
and therefore activation, of TRAF6, the E3 ligase that partner
with Ubc13 in the TLR signaling pathway (Fig. 6A). Con-
versely, increased TRAF6 autoubiquitination and increased
levels of Lys63 ubiquitin chains associated with TLR7 were
detected in GPS2-deficient B cells (Fig. 6B). Again, ubiquiti-
nation was not further increased upon LPS treatment, indi-
cating that removal of the inhibitor is sufficient for unleash-
ing the activation of the ubiquitin machinery even in the
absence of ligand stimulation.
These results, combined with our recent report of GPS2
playing an important role in controlling lipid metabolism
through inhibition RNF8/Ubc13 activity in the nucleus and
stabilization of the histone methyltransferase JMJD2/
KDM4A, suggested that distinct GPS2 functions within dif-
ferent cellular compartments similarly depend on the inhi-
bition of Ubc13-containing complexes (37). Based on our
previous data indicating that GPS2 can directly interact not
only with each of the specific E3 ligases present in the com-
plexes we investigated (namely TRAF2, TRAF6, or RNF8)
but also with Ubc13 itself (33, 37), we asked whether GPS2
could directly inhibit the enzymatic activity of the E2-con-
jugating enzyme rather than modulating a number of differ-
ent ligases. To address this question, we performed an in
vitro ubiquitination assay to assess the ability of the Ubc13/
Uev1A E2-conjugating enzyme complex to form ubiquitin
chains in the presence or absence of bacterially purified
recombinant His-GPS2. As shown in Fig. 6C, the direct syn-
thesis of ubiquitin chains by the Ubc13/Uev1A complex is
impaired in presence of GPS2, thus confirming that GPS2
inhibitory action does not require the presence of an E3
ligase. In particular, GPS2 significantly inhibits the elonga-
tion of ubiquitin chains, whereas neither the formation of
di-ubiquitin short chains nor the charging of avidin-tagged
or FLAG-tagged ubiquitin onto Ubc13 is affected by GPS2
(Fig. 6, C and D).
Together, these results suggest that GPS2 inhibitory activ-
ity within different signaling complexes depends on GPS2
directly inhibiting the enzymatic activity of Ubc13 to prevent
the synthesis of extended Lys63 ubiquitin chains. To confirm
this hypothesis in the context of pro-inflammatory signaling
pathways, we used a chemical inhibitor called NSC697923 to
inhibit Ubc13. NSC697923 was previously validated in a
model of diffuse large B cell lymphoma in which it was able to
suppress constitutive NF-B activation and cell prolifera-
tion/survival (65). As shown in Fig. 6 (E and F), both the
hyperactivation of p38 and JNK, as well as the increased
expression of pro-inflammatory target genes in GPS2-BKO
cells, were rescued by NSC697923. These results confirm
that Ubc13 hyperactivation is responsible for the phenotype
observed in GPS2-deficient splenic B cells and suggest that
Ubc13 unrestricted activation in absence of GPS2 underlies
the misregulation of multiple signaling pathways in GPS2-
BKO mice. Intriguingly, the most up-regulated gene in
GPS2-null B cells is the HECT E3 ligase NEDD4 (supplemen-
talTableS1 and Fig. 6G). HECT ligases promote ubiquitina-
tion through direct substrate ubiquitination rather than
through E2-mediated synthesis of ubiquitin chains, and
NEDD4, in particular, appears to have a preference for the
synthesis of Lys63 ubiquitin chains (66–68). Thus, we are
tempted to speculate that NEDD4 up-regulation might
reflect an attempt at compensating for the misregulation of
Ubc13-mediated Lys63 ubiquitination events.
Inhibition of BCR Signaling by GPS2 Is Required for Notch-
mediated Differentiation of MZ Cells—In B cells, TLR and BCR
signaling pathways present extensive cross-talk, including both
TLR-mediated sensitization of BCR activation, as well as com-
mon regulatory strategies and shared signaling mediators.
Among them, the use of Ubc13-dependent ubiquitination is a
key signaling mechanism downstream of multiple receptors
involved in immune responses (1, 31). Thus, based on GPS2
ability to inhibit Ubc13 activity in vitro, we asked whether its
inhibitory role extended to BCR activation. Upon stimulation
of splenic B cells with IgM, we observed a strong increase in
both basal and inducible phosphorylation of p38 in B cells iso-
lated fromGPS2-BKOcomparedwithWT littermates, suggest-
ing that GPS2 is required for restricting signal transduction
downstream of both BCR and TLR receptors (Fig. 7A). A
smaller, but consistent, increase in JNK activationwas observed
only in basal conditions, whereas ERK phosphorylation upon
IgM stimulation was slightly decreased (Fig. 7A). To confirm
that the increase in p38 activation is caused by GPS2-mediated
inhibition of ubiquitination, we asked whether activation of
FIGURE 4.ReducedB-1 B cell population inGPS2-BKOmice.A, flow cytometry analysis of splenic B-1 populations. Representative plots are shown, and
the cells are pregated as described above. B, splenic B-1 populations comparison.White bars, WT; black bars, GPS2-BKO (n 7). Bar graphs are S.E., and
the p value is calculated by two-tailed t test. C, flow cytometry showing B1-A and B1-B cell population in the bone marrow. White bars, WT; black bars,
GPS2-KO (n 4). D, IL-10 production by splenic B cells. Representative plots are shown for stimulated fully stained cells, stimulated fluorescence minus
one control (no IL-10 antibody added), and non-stimulated fully stained cells. All cells were incubated with monensin. IL-10 production by different B
cell subtypes is shown in histograms in the bottom row of plots. E, indirect quantification of IL-10 B cell percentage by mean fluorescence intensity.
White bars, WT; black bars, GPS2-BKO (n  3). F, cell yield obtained from peritoneal cavity lavage. G, flow cytometry analysis of peritoneal cavity B-1
populations. Representative plots are shown, and the cells are pregated as described above. H, peritoneal cavity B-1 populations comparison. White
bars, WT; black bars, GPS2-BKO (n  7). I, automatic clustering representation of the cytometry data set. Unsupervised SPADE clustering into 30–40
nodes/tree was performed using CD1d/5/21/23/43/93/45RO/IgD/IgM lineage marker channels, and the nodes were annotated based on the known
expression of lineage markers in various B cell subsets. A representative GPS2-BKO sample is shown. Fold increase of GPS2-BKO node percentages over
averaged WT is shown as color.
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Ubc13/TRAF6-dependent ubiquitin signaling downstream of
BCR receptor activation is affected by the lack of GPS2. As
shown in Fig. 7B, autoubiquitination of TRAF6 was indeed
higher in GPS2-deficient B cells rather thanWT splenic B cells
stimulated with IgM. Together, our data confirm that GPS2-
mediated inhibition of Lys63 ubiquitination plays a significant
role in modulating the activation of both BCR and TLR signal-
ing in B cells.
A B
C
IgG1 IgG2a IgG2b IgG3 IgA IgE IgM
*
*
*
0
10
2*10
3*10
4*10
5*10
6*10
1.5*10
2*10
2.5*10
3.5*10
3*10
4*10
9
9
9
9
9
9
7
7
7
7
7
7
pg
/m
l
NS NSNS
NS
D
0 
1 
2 
3 
4 
5 
6 
7 
8 
ltamcp1 Tnfa il6 inos
WT
BKO
**
**
*
*
*
m
R
N
A
 e
xp
r e
ss
io
n/
C
yc
lo
A
**
Ig
M
 M
F
I
MZ FO B1a B1b
**
NS
WT
BKO
**
8000
6000
4000
2000
0
WT
BKO
F
WT  0’
WT  4h Tg  4h
Tg  0’
0
5
10
15
20
25
CD14
Pam3
TLR1/2
ODN
TLR9
LPS
TLR4
Gardi
TLR7
*
*
*
m
R
N
A
 e
xp
re
ss
io
n/
C
yc
lo
A
0 100
200
300
400
500
TNF α
**
600
*
*
**
Pam3
TLR1/2
ODN
TLR9
LPS
TLR4
Gardi
TLR7
m
R
N
A
 e
xp
re
ss
io
n/
C
yc
lo
A
WT  0’
WT  4h Tg  4h
Tg  0’
0
NS
E
0 
10 
20 
30 
40 
50 
60 
70 
80 
il6
m
R
N
A 
ex
pr
es
si
on
/C
yc
lo
A
* **
10
20
30
40
50
60
70
0 
WT BKO WT BKO
il6
 -
TLR7
 -
TLR9
*
WT BKO
il6
 -
TLR4
2
4
6
8
10
12
0 
14
WT BKO
ccl4
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
5 
ccl3
***
m
R
N
A 
ex
pr
es
si
on
/C
yc
lo
A
WT BKO
 -
TLR7
 -
TLR7
2
4
6
8
10
12
0 
14
 
0 
0.2 
0.4
0.8 
1.0
1.2
GPS2
0.6 
WT BKO
 -
TLR7
**
*
JNK
p38
P-JNK
P-p38
0’ 15’ 30’ 60’LPS
WT B Cells BKO B Cells
0’ 15’ 60’30’
IkBa
pIKK
0’ 15’ 30’ 60’LPS
WT B Cells BKO B Cells
0’ 15’ 60’30’
-tubulinβ
m
R
N
A 
ex
pr
es
si
on
/C
yc
lo
A
FIGURE 5. GPS2 deletion promotes hyperactivation of TLR signaling. A, immunoglobulin profiling of IgG1, IgG2a, IgG3, IgA, IgE, and IgM is performed on
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Normalization was done against the unphosphorylated protein when possible or using tubulin as a loading control. Fold changes are calculated toward the
normalized level of each protein at time 0.D, RT-qPCR analysis of TLRs target genes in unstimulated B cells fromGPS2-BKO and control littermates. E, RT-qPCR
analysis of TLRs target genes upon stimulationwith Gardi, ODN, or LPS. Bar graphs represent the samplemean of three independent experiments S.D. *, p
0.05; **, p 0.01. F, gene expression analysis by RT-qPCR performed on RNA from wild-type GPS2-overexpressing macrophages (33) (Ap2-GPS2 transgenic
mice) upon treatment with indicated ligands. The data are representative of three independent experiments. Bar graphs represents the sample mean of
technical replicates S.D. *, p 0.05; **, p 0.01.
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Intriguingly, the strength of BCR signaling has been shown to
play a critical role in the cell fate decision between FO and MZ
cell types in the spleen. In particular, weak BCR signaling was
associated with MZ B cell development, whereas a strong BCR
signaling is thought to facilitate the commitment toward the
FO B cell lineage via inhibition of Notch2 signaling (69–72).
Accordingly, Notch2 haploinsufficiency leads to a marked
reduction in both MZ and B1 B cells (73). Based on Notch2
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target gene Deltex (Dtx1) being the second most significantly
down-regulated gene after GPS2 in GPS2-BKO cells (supple-
mental Table S1), we hypothesized that aberrant activation of
the BCR pathway and thus inhibition of Notch2 signaling could
be the underlying mechanism of the reducedMZ phenotype in
GPS2-BKO mice. In support of this hypothesis, we confirmed
that not only Dtx1, but also other Notch2 target genes, such as
Hes1 (Hairy enhancer of split 1) and Hes5 (Hairy enhancer of
split 5), were down-regulated in splenic B cells fromGPS2-BKO
whereas the expression of Notch2 receptor itself was un-
changed (Fig. 7C). Notably, the defect in gene expression was
dependent on both p38 and Ubc13 activation because gene
down-regulation was rescued by inhibiting either p38 or Ubc13
activity (Fig. 7C). Also, the down-regulation was specific to
sortedMZcells and not observed in the corresponding FOpop-
ulation (Fig. 7D). Thus, our results suggest that GPS2 require-
ment for MZ B cell differentiation in the spleen is likely tied to
the regulation of BCR signaling, with GPS2 deletion causing
exacerbated activation of BCR and therefore indirectly affect-
ing the activation of important Notch2-dependent cell fate
commitment genes.
Overall, we conclude that GPS2 plays a broad inhibitory
effect over the activation of different signaling pathways via
modulation of Ubc13 enzymatic activity (Fig. 7E). In particular,
our findings indicate that the presence of GPS2 in murine B
cells is essential for restricting the activation of the PI3K/AKT
andTLR/BCRpathways. Conversely, loss of GPS2 leads tomul-
tiple defects during B cell development because of aberrant
activation of Lys63 ubiquitination events and altered gene
expression programs downstreamof themisregulated signaling
pathways.
Discussion
Stringent regulation of pro-inflammatory pathways is critical
to allow for a rapid and effective response to infections and
other external injuries while preventing the aberrant and dam-
aging activation of autoimmune reactions and other forms of
chronic inflammation. Non-proteolytic ubiquitination medi-
ated by the E2-conjugating enzyme Ubc13 represents a critical
component of multiple pro-inflammatory signaling pathways
converging on the activation of the transcription factor NF-B.
Accordingly, it is an important regulatory step that can be neg-
atively controlled by endogenous inhibitors of NF-B activa-
tion, such as the deubiquitinases A20, CYLD, andMYSM1 (21,
23, 74, 75). In this manuscript, we characterize GPS2 as a novel,
important negative regulator of non-proteolytic ubiquitination
that acts directly on Ubc13 and inhibits the formation of
extended Lys63 ubiquitin chains synthetized by the Ubc13/
Uev1A complex. Mechanistically, our initial in vitro character-
ization of GPS2 inhibitory activity suggests possible similarities
to the mechanism of action of another Ubc13 inhibitor that is
critical for the regulation of DNA damage response, the
deubiquitinating enzyme OTUB1 (76–78). However, more
detailed structural studies will be required to fully elucidate the
mechanistic details of GPS2 inhibition toward the Ubc13
complex.
The identification of GPS2 as an endogenous inhibitor of
Ubc13 activity has critical implications not only for immune
response pathways but also for other key cellular processes rely-
ing on Lys63 ubiquitination events. Further studies will be
required for addressing each case individually with consider-
ation of the cross-talks among different ubiquitin machineries.
However, the initial observations presented here, together with
previous reports, seem to confirm that GPS2-mediated inhibi-
tion of Lys63 ubiquitination is functionally critical for a number
of pathways that utilize Ubc13, including TNFR1, TLR, BCR,
and PI3K/AKT signaling pathways.
In the context of pro-inflammatory responses, here we have
elucidated, in overexpressingmacrophages andGPS2-deficient
B cells, the role of GPS2 in the response to a number of TLR
ligands. Overall, our data confirmGPS2 critical role in prevent-
ing the constitutive, basal activation of the signaling cascade
that links liganded TLR receptors to the transcriptional regula-
tion of NF-B target genes. These results are consistent with
studies published during the compilation of this manuscript
reporting that GPS2 depletion inmacrophages promotes a pro-
inflammatory gene signature corresponding to enhanced TLR
signaling (38). Intriguingly, our results indicate that the extent
of the changes in gene expression associated with GPS2 reduc-
tion/deletion is likely reflective of broad effects on the pro-
inflammatory signaling cascades rather than being limited to a
sole transcriptional role for GPS2 as part of the NCoR/SMRT
corepressor complexes.
Constitutive activation of NF-B signaling is widely reported
as a pro-survival strategy in cancer, and the transduction path-
ways upstream of NF-B nuclear translocation are affected in a
large number of hematological malignancies (29, 79–82). In
particular, somatic mutations leading to constitutive NF-B
activation have been identified in negative regulators of non-
proteolytic Lys63 ubiquitination events, such as the deubiquiti-
nases and tumor suppressors CYLD and A20 (26, 30). Consti-
tutive activation of the NF-B pathway is also a component of
the oncogenic program promoted by viral proteins, such as the
human T cell leukemia virus (HTLV-1) activator Tax (83), that
promote GPS2 down-regulation upon viral infection (84, 85).
Because recent work indicates that Tax-induced NF-B activa-
tion depends on viral hijacking of the endogenous RNF8 and
Ubc13 enzymes to promote Lys63 ubiquitination (86), we are
tempted to speculate that removal of GPS2-mediated inhibi-
FIGURE 6.GPS2 restricts TLR signaling through inhibitionofUbc13activity.A, TRAF6 autoubiquitination upon LPS stimulation ismeasuredby IP-WBusing
an antibody specific for Lys63-linked Ub chains after 24 h of transient HA-GPS2 overexpression in 293T cells. CTL, control. B, IP-WB using anti-TLR7 and total Ub
antibody in B cell from WT and GPS2-KO B cells stimulated with Gardi. C, in vitro ubiquitination assay performed in the presence or absence of recombinant
His-GPS2. E1 and Ubc13 are initially loadedwith biotin-labeled ubiquitinGPS2. Then Uev1A is added, and excess unlabeled ubiquitin and nascent ubiquitin
chains are monitored after 5 min at 37 °C byWestern blotting for ubiquitin or avidin-HRP. Loading and unloading of ubiquitin from Ubc13 (thioester bond) is
measured via avidin-HRP WB under native conditions. D, in vitro ubiquitination assay using FLAG-Ub to preload Ubc13 prior to Uev1a addition. E, Western
blotting analysis of LPS induced activation of p38 and JNK showing that inhibition of Ubc13 activity by the smallmoleculeNSC697923 is sufficient to rescue for
the lackofGPS2. F, bothUbc13 inhibitionbyNSC697923andp38 inhibitionbySB203580 rescue thebasal activationof pro-inflammatory target genes (Fig. 5D).
G, expression of Nedd4 by RT-qPCR in splenic B cells.
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tion of Ubc13 activity might be a critical component of the viral
strategy for controlling the growth and survival of HTLV-in-
fected cells. These observations together raise the intriguing
possibility that GPS2 itself could serve a tumor suppressive role
in cells where the aberrant constitutive activation of NF-B
signaling contributes to tumor development and progression.
This hypothesis is in agreement with recent reports of GPS2
being mutated or deleted in different tumor types (47, 87–94),
thus providing the rationale for further dedicated studies to
assess the role of GPS2 in cancer.
Understandably, the proper integration of signals coming
from multiple receptors that share Ubc13 as an important
signaling mediator, including BCR, TLR, BAFF, and CD40, is
critical for a number of functions, including the maturation
and homeostasis of B cells, as well as their ability to mount
proper immune responses. Although this study has focused
on the role played by GPS2 during mouse B cell develop-
ment, further studies will be required to investigate to what
extent GPS2-deficient mice can respond to infections and
injuries through normal innate and adaptive immune
responses and whether the lack of GPS2 affects the develop-
ment of autoimmune diseases.
Here, the phenotypical characterization of the normal devel-
opment of GPS2-BKOmice has revealed a broad role for GPS2
in early and late B cell developmental stages, with the condi-
tional deletion of GPS2 in the B cell lineage leading to a mild
accumulation of pre-B cell in the bonemarrow and a significant
decrease in splenic MZ and B-1 cells. Intriguingly, our data
support a model in which both phenotypes are related to the
loss of GPS2-mediated regulation of Ubc13 activity. Unre-
stricted activation of AKT in the earliest stages of B cell devel-
opment, prior to mature BCR expression, appear to alter the
activation of a FOXO1-dependent transcriptional gene net-
work that is required for immunoglobulin chain recombination
and receptor editing. Later defects are instead associated with
the hyperactivation of pathways regulated by Ubc13-mediated
Lys63 ubiquitination leading to constitutive activation of BCR
signaling, preventing Notch2-mediated cell fate decision
events.Notably, in both instances the same target genes that are
downstream targets of the pathways that are regulated byGPS2
in a non-genomic fashion through inhibition of Ubc13 activity
are also directly regulated byGPS2 as a transcriptional cofactor.
Thus, our results together support a comprehensive model in
which the genomic andnon-genomic actions ofGPS2 in the cell
are exquisitely coordinated.
To our initial surprise, the GPS2-BKO mice phenotype in
regard to B1 andMZ cells is very similar to that of mice deleted
of Ubc13 itself (95). However, similar defects are observed in
mouse knock-out models of both activators and inhibitors of
BCR/TLR signaling (96) (i.e. TAB2/3, A20, IBNS, TRAF6,
TAB2/3, and MALT1) (26, 97–100). We speculate that these
apparent discrepancies are indicative of the fact that having
constitutive or exacerbated signaling, at least during particular
stages of development, can be as damaging as having a reduced
or impaired response, thus supporting the importance of
endogenous regulators, such as GPS2, to maintain tight regula-
tion in both directions.
Lastly, it is noteworthy that naïve GPS2-BKO mice present
increased plasma levels of natural antibodies, particularly
IgM, despite the lower number of innate-like B cells. This is
consistent with higher level of serum Igs observed in other
models of BCR/TLR hyperactivation (26, 100–102), whereas
the production of natural antibodies is usually impaired
upon deletion of key mediators of both pathways (96, 99,
103). Thus, the increase in natural antibody production in
vivo is in accord with the constitutive activation of TLR/BCR
signaling observed in GPS2-null B cells. This suggests that
the reduced number of innate-like B cells in GPS2-BKOmice
might be functionally compensated by their enhanced acti-
vation. In addition, secreted IgM would further enhance
BCR signaling while restricting the size of the B1 and MZ
compartments, thus possibly establishing a forward feed-
back loop that influences B cell survival and homeostasis at
steady state (104, 105).
In conclusion, the characterization of GPS2 B cell-specific
conditional knock-out mice has confirmed in vivo the impor-
tant role played by GPS2 in the regulation of Ubc13 enzymatic
activity withinmultiple signaling pathways and revealed a com-
prehensive view of how the coordinated regulation of non-pro-
teolytic ubiquitination in different signaling pathways con-
verges in mediating key developmental steps during B cell
development.
Experimental Procedures
Mice—aP2-GPS2-overexpressing mice were previously de-
scribed (33). Conditional Gps2flox/flox mice were generated by
inGenious Targeting Laboratory. The 9.52-kb region used to
construct the targeting vector was first subcloned from a posi-
tively identified C57BL/6 (RP23: 91G16) BAC clone into a
2.4-kb backbone vector (pSP72, Promega) containing an
ampicillin selection cassette. The total size of the targeting con-
struct (including vector backbone and Neo cassette) is13.62
kb. The region was designed such that the short homology arm
extends2.55 kb 3	 to exon 6. The long homology arm ends 5	
FIGURE 7. Inhibition of BCR signaling by GPS2 is required for Notchmediated differentiation of MZ cells. A, immunoblot analysis of MAPK kinases p38,
JNK, and ERK activation upon BCR stimulation with 10 g/ml IgM for the indicated times. On the right is shown quantification of the blots by volume
densitometry. Normalizationwasdone against theunphosphorylatedprotein. Fold changes are calculated toward thenormalized level of eachprotein at time
0. B, TRAF6 autoubiquitination upon IgM stimulation of splenic B cells from wild-type and GPS2-BKO mice measured by IP-WB using an antibody specific for
Lys63 ubiquitin chains. C, expression of Notch2 target genes Hes1, Hes5, and Deltex by RT-qPCR in splenic B cells from wild-type and GPS2-BKO mice. The
reduced expression observed in GPS2-BKO cells is similarly rescued by inhibiting Ubc13 or p38 activity. D, expression of Notch2 target genes Hes1, Hes5, and
Deltex by RT-qPCR in marginal zone and follicular zone B cells sorted from splenocytes of WT and GPS2-BKOmice. Bar graphs represents the sample mean of
three independent experiments S.D. *, p 0.05; **, p 0.01. E, graphical summary. GPS2 mediated regulation of TLR, BCR, and AKT signaling pathways is
achieved through inhibition of Ubc13 enzymatic activity. B cell-specific deletion of GPS2 results in decreased expression of FOXO1-dependent genes that are
required for Ig recombination and defective development of bonemarrow B cells at the pre-B cells stage. GPS2 is also required at later stages of development
to prevent the constitutive activation of BCR and TLR signaling pathways and restrict the production of natural antibodies. Strong BCR is not permissive for
Notch2 signaling and leads to reduced differentiation of MZ B cells.
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to exon 3 and is 6.07 kb long.ApGK-gb2 loxP/FRTNeo cassette
is inserted on the 3	 side of exon 6, and the single loxP site is
inserted 5	 of exon 3. The target region is 0.90 kb and includes
exon 3–6. The targeting vector was linearized byNotI and then
transfected by electroporation of BA1 (C57BL/6 
 129/SvEv)
hybrid embryonic stem cells. After selection with G418 antibi-
otic, surviving clones were expanded for PCR analysis to iden-
tify recombinant ES clones and control for retention of the
third LoxP site. Secondary confirmation of positive clones was
performed by Southern blotting analysis prior to microinjec-
tion into C57BL/6 blastocysts. The resulting chimeras with a
high percentage agouti coat color were mated to wild-type
C57BL/6 mice to generate F1 heterozygous offspring. The Neo
cassette was excised by crossing with FLP mice (The Jackson
Laboratory) to generate F2 heterozygous mice with Neo dele-
tion in somatic cells and F3 heterozygous mice with Neo dele-
tion in germ cells. Homozygous Gps2flox/flox mice were then
used for crossing with heterozygous 129sv CD19-Cremice (48)
(The Jackson Laboratory). The CD19 promoter specifically
directs expression at the earliest stages and throughout B-lym-
phocyte development and differentiation (48). Because the Cre
cassette is inserted into exon 2 of CD19 gene, functionally dis-
rupting the gene, homozygous CD19-Cre mice are CD19-defi-
cient. However, heterozygous mice are phenotypically normal
and can be used for specific deletion of floxed targets in B-lym-
phocytes (48). Wild-type mice used as control for all analyses
presented here were littermates Gps2flox/flox/CD19Cre. All
experiments are done with mice 10–16 weeks old.
Flow Cytometry Analysis and Sorting—Bone marrow cells
were flushed from femoral bone by flush, peritoneal cavity cells
were isolated by lavage of the peritoneal cavity, and splenic B
cells were isolated from single cells suspension of total spleno-
cytes prepared according to standard protocols (106). B cell
purification was achieved by magnetic depletion using the
MACS Pan B cells isolation kit (Miltenyi Biotech). Purity of the
B cell populations was verified by flow cytometric analysis with
CD19, CD11b, andCD3 labeling. Flow cytometry analyses were
performed using the following anti-mouse Abs: BV510 anti-
B220, FITC anti-CD3, PE anti-CD23, PE-594Dazzle anti-IgM,
APC anti-CD19, PerCPCy5.5 anti-CD21, PE Cy7 anti-CD5
(Biolegend); BV395 anti-IgD, BV421 anti-CD1d, BV650 anti-
AA4.1, BUV737 anti-CD43, FITC anti-IL-10, BV496 anti-CD3
(BD Biosciences), and A700 anti-CD11b (Ebioscience). Single
cell suspensions were stained with NIR Zombie dye, washed,
preblocked with mouse FcBlock (Biolegend), and stained with
antibody cocktails in the presence of Brilliant Violet buffer (BD
Biosciences). Ultracomp beads (eBioscience) stained with
abovementioned antibodies andArC beads (Life Technologies)
stained with NIR Zombie dye were used for compensation in
FACSDIVA. All data were acquired on a FACSARIA II SORP
(BD Biosciences). To minimize fluorescence data variability,
Ultra Rainbow Beads (Spherotech) were used for target value
tracking. At least 200,000 events were collected from each
sample. At least 96% purity was confirmed for all sorted
populations.
Flow Cytometry Data Analysis—All manual analysis was per-
formed by a blinded investigator using FlowJo 10, and statistical
analysis was performed with GraphPad Prism 5. For SPADE
automated clustering, automatically compensated data were
imported into Cytobank, and all consequent analysis was per-
formed within Cytobank platform (107) Live, single-particle,
CD3CD11bCD19 events were extracted and analyzed;
events were down-sampled at 80% clustered into 30–40 nodes/
tree using CD1d, CD5, CD21, CD23, CD43, CD93, B220, IgD,
and IgM as clustering channels. Trees were annotated based on
the known expression of signature markers.
Cell Culture and Treatments—B cells purified from spleen
of Gps2/ and wild-type littermates were cultured at 106
cells/ml in RPMI 10% FBS, 100
 penicillin/streptomycin,
and treated with 1 g/ml LPS (TLR4 ligand), 1 M of ODN
2395 (TLR9 ligand), or 1 g/ml gardiquimod (TLR7 ligand)
(Invivogen) for 4 h. Treatment with 10 g/ml of purified rat
anti-mouse IgM (BD Pharmingen) was performed in the
same culture condition for different time courses. For IL-10
stimulation and phenotyping, spleen cells were stimulated
for 5 h in the presence of 10 g/ml LPS, 50 ng/ml phorbol
12-myristate 13-acetate, and 500 ng/ml ionomycin in pres-
ence of 2 M monensin as described previously (108) stained
for surface markers, fixed with IC fixation buffer (Bioleg-
end), permeabilized with IC permeabilization/wash buffer
(Biolegend), and stained for IL-10. 293T cells were cultured
in 4.5 g DMEM/liter glucose, 10% FBS, and 100
 penicillin/
streptomycin. For cell transfection, Lipofectamine 2000 was
used following the manufacturer’s protocol (Life Technolo-
gies). After 24 h, the cells were treated 1 g/ml LPS for 5 or
10 min, lysated, and then subjected to IP/WB. Bone marrow-
derived macrophages were isolated as differentiated in vitro
as previously described (33). For gene expression analysis
they were treated with 10 g/ml lipopeptide Pam3CSK4
(Pam3) TLR1/2 activator, 1 g/ml LPS TLR4 activator, 10
g/ml imidazoquinoline compound Gardi TLR7 activator,
or 1 M CpG oligodeoxynucleotides (ODN 2395) TLR9 ago-
nist for 4 h. In rescue experiments cells were treated for 4 h
with chemical inhibitors at the following concentrations:
NSC697923 2 M (Sigma-Aldrich, Ubc13 inhibitor),
SB203580 25 M (Invivogen, p38 MAPK inhibitor).
H&E and Immunohistochemistry Staining of Splenic
Sections—Cryosections from Gps2-BKO mice and wild-type
littermates were prepared at 10-m thickness, fixed in 10% for-
malin solution, and stainedwith hemoatoxilin solution (Fisher-
brand) and eosin solution (Fisherbrand) according to standard
protocols. For immunohistochemistry, sections were blocked
with 10% donkey serum, 1%BSA and then stainedwith primary
antibody overnight at 4 °C and secondary antibody for 1 h at
room temperature. The antibodies used are rat anti-mouse
MOMA-1 (AbD Serotec-Bio-Rad) and HRP-conjugated anti-
RAT (Cell Signaling). The reaction was developed using the
DAB liquid substrate dropper system (Sigma) following the
manufacturer instructions.
Western Blotting and Abs—Whole cell lysates were prepared
in radioimmune precipitation assay buffer, and protein extracts
were resolved by SDS-PAGE and then electrotransferred onto
PVDFmembrane. The followingAbswere used: anti-GPS2was
generated in rabbit against a peptide representing amino acids
307–327 (33); anti-Ubc13 (YD-16), anti-JNK1/2 (FL), anti-
TRAF6 (H-274), anti-EKR (K23) (Santa Cruz Biotechnology);
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anti-phospho JNK (4668), anti-phospho p38 (4511S), anti-IkBa
(9247), anti-p38 (9212), and anti-phospho ERK1/2 (E10) (Cell
Signaling); mouse anti-B-tubulin (Sigma); mouse anti-HA
(Upstate Biotechnology); and anti-polyubiquitin-Lys63 linkage-
specific (Enzo Life Science).
In Vitro Ubiquitination and Protein Purification—Ubiquiti-
nation assays were carried out at 37 °C in 50 mM Tris-HCl,
pH 7.6, 50 mM NaCl, 5 mM MgCl2, 5 mM ATP, 1
 ubiquitin
aldheide, and 2 mM DTT. GPS2 was produced as a His tag
fusion protein in BL21 Escherichia coli, resin-purified on
nickel-nitrilotriacetic acid beads, and eluted accordingly to
manufacturer’s protocol (Life Technologies). Purified
recombinant enzymes and ubiquitin were purchased from
Boston Biochem. The reaction was first assembled on ice
with 50 nM recombinant E1, 1 M Ubc13, 5 g of tagged Ub
(either Flag-tagged or biotin-tagged) with or without GPS2.
Ubiquitination was then promoted by adding 1 M Uev1A
and unlabeled ubiquitin in excess (20 g). The reactions
were stopped after 5 or 10 min at 37 °C by boiling in DTT-
containing SDS loading buffer, and proteins were resolved by
SDS-PAGE and immunoblotted. For native gels, DTT was
excluded from the reaction, we used DTT-free SDS loading
buffer, and samples were not boiled.
Chromatin Immunoprecipitation, RNA Extraction, RT-
qPCR, and RNA-Seq—ChIP was performed as previously
described (37). Total RNA was prepared with RNeasy plus
mini kit (Qiagen) according to the manufacturer’s protocol.
RNA was retrotranscribed into cDNA using iScript reverse
transcription supermix for RT-qPCR (Bio-Rad), and qPCR was
performed using the Fast SYBRGreenMasterMix (Life Tech-
nologies) according to themanufacturer’s protocol. All samples
were run in triplicate using a ViiA7 qPCR machine (Appied
Biosystem), and normalization was calculated to the house-
keeping gene cyclophilin A. Significance of gene expression
analyses was calculated by two-tailed, two-sample t test with
unequal variance among replicate experiments as indicated in
the figure legends. The sequences of oligonucleotides used for
gene expression analysis are available upon request. For RNA-
Seq experiments RNA quality was assessed on the Agilent 2100
Bioanalyzer (Boston University Medical Center Microarray
Core). cDNA libraries were prepared either with the NEBNext
ultra directional library preparation kit for Illumina or with the
Illumina TruSeq stranded total RNA sample prep kit with
rRNA depletion by RiboZero Gold and then sequenced on a
HiSeq2500 (single-strand, 50-bp reads).
Bioinformatics Analysis of RNA-Seq Samples—The sequenc-
ing reads were aligned to the mouse genome mm8 by using
bowtie (109), and the aligned sequencing reads were counted
over gene exons by using HOMER that computed also the
RPKM values. The differentially expressed genes between
KO and WT samples were statistically defined by a two-
tailed, two-sample t test between the replicates (p value 
0.05). The heat maps of differential expressed genes were
displayed by using R packages “pheatmap” and “gplots”
(heatmap.2() functions). To characterize the differential use
of V, D, and J segments, we have downloaded the sequences
from IMGT database, and their expression levels were com-
puted with RSEM (110). The RNAseq data are available on
the GEO website under accession number GSE92751.
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